DAB2IP down-regulates HSP90AA1 to inhibit the malignant biological behaviors of colorectal cancer

Abstract

These findings provide evidence that DAB2IP-based therapy may enhance the anticancer effect of HSP90AA1 inhibitors, and combined targeting of DAB2IP and HSP90AA1 may be a powerful treatment strategy to combat CRC.